A5008333390- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Intraocular Surgery and Lenses
- Retinal and Macular Surgery
- Retinal Development and Disorders
- Ocular Infections and Treatments
- Blood Pressure and Hypertension Studies
- Salivary Gland Disorders and Functions
- Neuroinflammation and Neurodegeneration Mechanisms
- melanin and skin pigmentation
- Ophthalmology and Eye Disorders
- Neurosurgical Procedures and Complications
- Neurological Disorders and Treatments
- Spinal Fractures and Fixation Techniques
- Neurological Complications and Syndromes
- Venous Thromboembolism Diagnosis and Management
- Spine and Intervertebral Disc Pathology
- Blood Coagulation and Thrombosis Mechanisms
- Traumatic Ocular and Foreign Body Injuries
- Child Abuse and Related Trauma
- Complement system in diseases
- Mitochondrial Function and Pathology
University College Dublin
1999-2024
Mater Misericordiae University Hospital
1999-2024
Bon Secours Hospital Dublin
2021-2022
Mater Private Hospital
2022
University of Zurich
2021
Hemel Hempstead Hospital
2020
University College London
2005
Moorfields Eye Hospital
2005
Royal Victoria Eye and Ear Hospital
2003-2004
Geographic atrophy (GA) is an advanced and irreversible form of age-related macular degeneration (AMD). Chronic low grade inflammation thought to act as initiator this degenerative process, resulting in loss photoreceptors (PRs), retinal pigment epithelium (RPE) the underlying choriocapillaris. This review examined challenges clinical trials date which have sought treat GA, with particular reference successful outcome C3 complement inhibition. Currently, optical coherence tomography (OCT)...
The main purpose of the study was to report estimated incidence, cumulative rate, risk factors and outcomes submacular haemorrhage (SMH) with loss vision in neovascular age-related macular degeneration (nAMD) receiving intravitreal injections (IVT) vascular endothelial growth factor (VEGF) inhibitor routine clinical practice.Retrospective analysis treatment-naïve eyes IVTs VEGF inhibitors (ranibizumab, aflibercept or bevacizumab) for nAMD from 1 January 2010 31 December 2020 that were...
To evaluate the proportion, predictors, and outcomes of patients with neovascular age-related macular degeneration (nAMD) treated a high burden VEGF inhibitor intravitreal (IVT) injections after 2 years in routine clinical practice.
Purpose: Diabetic retinopathy (DR) is a preventable cause of blindness detectable through screening using retinal digital photography. The Irish National Retina Screening (DRS) programme, RetinaScreen, provides free services to patients with diabetes from aged 12 years and older. A technical failure (TF) occurs when imaging ungradable, resulting in delays the diagnosis treatment sight-threatening disease. Despite their impact, causes TFs, indeed utility interventions prevent them, have not...
Background/Aims To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 in treatment cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. Methods A multicentre, international, database observational study recruited 322 eyes initiating therapy real-world practice 5 years. The main outcome measure was mean change EDTRS letter scores visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage VA >6/12 (70 letters), number injections...
To compare 1-year outcomes of eyes with diabetic macular edema (DME) treated in routine clinical practice based on the proportion visits where intravitreal VEGF inhibitor injections were delivered.
ou non, émanant des établissements d'enseignement et de recherche français étrangers, laboratoires publics privés.
Objective To study the uptake of annual diabetic retinopathy screening and 5-year trends in detection screen-positive non-diabetes-related eye disease a cohort annually screened individuals. Design Retrospective attendance grading analysis. Setting Community-based centres for Diabetic RetinaScreen Programme. Participants 171 557 were identified by programme to be eligible screening. 120 048 individuals over age 12 consented attended at least one appointment between February 2013 December...
To determine the prevalence of glaucoma among patients referred to a service with suspicious disc photographs from diabetic retinopathy (DR) screening program.A clinical audit all attending single-center DR program in Mater Misericordiae University Hospital, Dublin, between July 2010 and October 2011 was conducted minimum follow-up 30 months. The uses trained technician graders assess 2-field color retinal for features DR. Recently, enhanced so that optic discs are also assessed signs...
A 56-year-old woman with primary open-angle glaucoma in an only eye presented hypertrichosis after using Latanoprost to lower IOP. After trabeculectomy adjunctive Mitomycin C, IOP was well controlled and antiglaucoma medications could be discontinued. At eight-month follow-up the abnormal eyelashes had disappeared.
To assess clinical outcomes of cataract surgery in eyes treated with intravitreal injections for cystoid macular oedema (CMO) secondary to retinal vein occlusions (RVOs). Eyes receiving CMO RVOs that underwent extraction were identified from the Fight Retinal Blindness! Registry and matched 1:1 by 9 parameters phakic controls also same condition. VA change at 12 months, central subfield thickness (CST) injection frequency before after compared between two groups. The effect baseline features...
ABSTRACT Background We aimed to describe a 2‐year outcome of eyes managed by practitioners benchmarked using funnel plot their frequency treatment vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO). Methods A multicentre, international, observational study 29 doctors in 12 countries managing 1110 with RVO commencing VEGF between 1 January 2012–2022 tracked the Fight Retinal Blindness! registry. Results identified 3 outlying ‘intensive’ (managing...
Background/aims To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naïve hemiretinal vein occlusion (HRVO) compared branch (BRVO) central (CRVO) variants in routine clinical care. Methods A database observational study recruited 79 HRVO eyes, 590 BRVO eyes 344 CRVO that initiated therapy over 10 years. The primary outcome was mean change visual acuity (VA—letters read on a logarithm minimal angle resolution chart)...
Objective: To assess the patterns of patient generated aerosol in context ophthalmic surgery and examinations. inform medical teams regarding potential hazards suggest mitigating measures. Methods: Qualitatively, real-time time videography assessed exhalation from simulated patients under different clinical scenarios using propylene glycol an e-cigarette. Quantitatively, high-speed Schlieren imaging was performed to enable high resolution recordings analysable by MATLAB technical computing...
Background: Patient non-attendance following referral to hospital is a significant challenge, in particular, for persons with diabetes. Aim: We sought determine the impact on both visual acuity and subsequent follow-up retinopathy grade of patients when they fail attend Diabetic Retinopathy Treatment (DRT) Centers from RetinaScreen (DRS). Methods: A retrospective analysis discharged DRT due multiple consecutive missed appointments between January 2016 June 2021. Patients were compared...
Purpose: Assess the relationship between subretinal fluid (SRFL), intraretinal fluid, and visual outcomes of neovascular age-related degeneration in routine clinical practice. Methods: Treatment-naive eyes enrolled Fight Retinal Blindness! registry after January 2017 were identified. Lesion activity was graded at each visit as inactive, active not SRFL only (A-NSRFL only), or (A-SRFL only). Eyes grouped based on initial follows: 1) initially A-NSRFL 2) A-SRFL , their predominant status over...
To report the 36-month treatment outcomes of eyes with neovascular age-related macular degeneration (nAMD) receiving vascular endothelial growth factor (VEGF) inhibitors in daily practice who did not develop either subretinal fibrosis (SRFi) or atrophy (MA).This is a retrospective analysis data from Fight Retinal Blindness registry. Treatment-naïve starting intravitreal injection VEGF for nAMD January 1, 2010, to September 2017, and have SRFI MA at baseline were tracked.We identified 2478...